UACR AND eGFR TESTING
ADA AND KDIGO GUIDELINES RECOMMEND THAT UACR SHOULD BE USED TO TEST FOR ALBUMINURIA IN T2D ALONG WITH eGFR AT LEAST ONCE A YEAR1-3
BY STARTING LIFESTYLE MODIFICATIONS AND TREATMENT OPTIONS AS EARLY AS POSSIBLE, MORE CAN BE DONE TO PROTECT PATIENTS WITH CKD AND T2D FROM CV DEATH AND LONG-TERM KIDNEY DAMAGE
Following medical guidelines, both UACR and eGFR are critical for taking timely action against renal damage and CV risk1,2
ADA guidelines established a treatment target for UACR which recommends that UACR should be reduced by at least 30% in patients with CKD and T2D and a UACR level above 300mg/g1-3
Patients with T2D who have albuminuria may be suitable for additional treatment, even if their eGFR is preserved, to protect against deadly CV events and limit further kidney damage1-3
Thank you for visiting our site. The questions you'll see throughout are completely voluntary.
When leveraged together, increasing levels of albuminuria and reduced rates of eGFR indicate clinical manifestations of kidney damage and increased CV risk2
ADA=American Diabetes Association; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; GFR=glomerular filtration rate; KDIGO=Kidney Disease Improving Global Outcomes; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.
References:
- Campion CG, et al. Can J Kidney Health Dis. 2017;4. doi:10.1177/2054358117705371. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1–150. Return to content
- American Diabetes Association Professional Practice Committee. Diabetes Care. 2022;45(suppl 1):S1–S264. Return to content
Follow:
© 2022 Bayer AG
Last updated in June 2022
This website is intended to provide information to an international audience of healthcare professionals outside the USA and UK.
- PP-KER-ALL-0077-1
